Lundbeck Secures Japanese Approval for Vyepti, Expanding Migraine Portfolio in Asia
Event summary
- Lundbeck's Vyepti (eptinezumab) received marketing authorization from Japan's MHLW for migraine prevention in adults.
- Approval supported by Phase III SUNRISE trial and SUNSET long-term extension study in Japanese patients.
- Vyepti is the only IV CGRP-targeted preventive treatment approved for migraine in Japan.
- Lundbeck prepares for its first independent launch in Japan, building on 25 years of market presence.
The big picture
Lundbeck's approval of Vyepti in Japan marks a strategic milestone in its expansion into the Asian migraine market. With migraine affecting 8.4%–11.0% of Japan's population and costing the economy $3 billion annually in lost productivity, Vyepti's IV CGRP-targeted therapy offers a differentiated treatment option. This approval also underscores Lundbeck's long-term commitment to brain health in Japan, positioning the company for independent market operations and potential revenue growth.
What we're watching
- Market Penetration
- How Lundbeck will position Vyepti against existing migraine treatments in Japan's competitive landscape.
- Revenue Growth
- Whether the Japanese approval can drive significant revenue growth for Lundbeck in Asia.
- Regulatory Strategy
- The pace at which Lundbeck seeks additional approvals for Vyepti in other Asian markets.
Related topics